NR-566 Week 5 Assignment: Immunization – Pneumococcal 23-valent polysaccharide (PPSV23) | Download To Score An A

Immunization Assignment Brandie Ingram Chamberlain University College of Nursing NR-566 Pharmacology for Primary Care Dr. Angela Thompson Nov 2020 This study source was downloaded by from CourseH on :05:54 GMT -06:00 NR 566 WEEK 5 2 Immunizations are an important part of becoming a healthy adult. The process in which a person is made resistant to infectious diseases and illness is through immunizations or vaccines. Vaccines are known to protect people from diseases like Diphtheria, Tetanus, and Pertussis (DTaP) and pneumococcal disease. This paper will highlight the name of 2 diseases and their respected vaccines, along with important information regarding those vaccines. PPSV23 Pneumococcal disease is a pneumococcal infection caused by Streptococcus pneumoniae bacteria. The preventable vaccination for this bacterium is the Pneumococcal 23- valent polysaccharide vaccine (PPSV). Its trade name is Pneumovax 23. This vaccine is an inactivated type and is contraindicated in persons with previous history of anaphylactic or severe allergic reaction to any component of the pneumococcal vaccine, have a cochlear implant, or those with a chronic cerebrospinal fluid leak (Micromedex, 2020). Precautions include patients who are immunocompromised (may not have expected antibody response) (Micromedex, 2020). Patients who have an acute illness (vaccination should be deferred) (CDC, 2020). Patients who have a severe cardiovascular or respiratory dysfunction (a systemic reaction could occur) (Micromedex, 2020).When also giving the Zostavax® vaccine, these vaccines should be given separately (at least 4 weeks apart) to avoid a reduced immune response to the Zoster vaccine (CDC, 2020). Adverse drug reactions that can occur are erythema and/or tenderness at injection site, myalgia, and fatigue. The minimum age to receive vaccine is 2 years old and older (ACIP, 2020). All patients between 2 years old and 65 years old receive a one-time dose of 0.5 ml intramuscularly or subcutaneously (ACIP, 2020). Special situations include patients who have never received any pneumococcal vaccines should first be administered a dose of PCV13. After